iwCLL 2021 | Sequencing of targeted therapies for CLL
Adrian Wiestner, MD, PhD, National Institutes of Health, Bethesda, MD, talks on the different strategies to sequence targeted therapies for patients with chronic lymphocytic leukemia (CLL). Dr Wiestner explains that venetoclax is effective for patients who develop resistance to BTK inhibitors and that similarly BTK inhibitors have proven to have a positive impact on patients who have progressed on venetoclax. Dr Wiestner further comments on novel non-covalent BTK inhibitors that could be used in patients previously treated with covalent BTK inhibitors. This interview took place at the 19th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held virtually in 2021.
Disclosures
Adrian Wiestner, MD, PhD, is supported by the Intramural Research Program of the National Heart, Lung, and Blood Institute, NIH and has collaborative research agreements and research support from Pharmacyclics LLC, an Abbvie company, Acerta LLC, a member of the AstraZeneca Group, Merck, Nurix, Genmab and Verastem.
